Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Shiga, Hideaki*; Taki, Junichi*; Washiyama, Koshin*; Yamamoto, Jumpei*; Kinase, Sakae; Okuda, Koichi*; Kinuya, Seigo*; Watanabe, Naoto*; Tonami, Hisao*; Koshida, Kichiro*; et al.
PLOS ONE (Internet), 8(2), p.e57671_1 - e57671_8, 2013/02
Times Cited Count：20 Percentile：69.56(Multidisciplinary Sciences)Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*
KEK Proceedings 2012-7, p.35 - 40, 2012/10
no abstracts in English
Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate siteOgawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Onoguchi, Masahisa*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Odani, Akira*; Saji, Hideo*
Annals of Nuclear Medicine, 23(10), p.843 - 848, 2009/12
Times Cited Count：10 Percentile：32.93(Radiology, Nuclear Medicine & Medical Imaging)Rhenium is one of the most valuable elements for internal radiotherapy because Re have favorable physical characteristics. However, there are problems when proteins such as antibodies are used as carriers of Re. Labeling methods require the complicated processes. Therefore, we planned the preparation by a simple method and evaluation of a stable Re-labeled antibody. For this purpose, we selected Re(I) tricarbonyl complex as a chelating site. A7 was used as a model protein. Re-labeled A7 was prepared by directly reacting a Re(I) tricarbonyl precursor with A7. Re-(CO)
-A7 were prepared with radiochemical yields of 23-28%. After purification, Re-(CO)-A7 showed a radiochemical purity of over 95%. In biodistribution experiments, Re-labeled A7 showed high uptakes in the tumor.
Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal modelOgawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
Journal of Nuclear Medicine, 48(1), p.122 - 127, 2007/01
We developed a highly stable rhenium-186 (Re)-MAG3 complex-conjugated bisphosphonate, (Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with Re-HEDP. In this study, we evaluated the therapeutic effects of Re-MAG3-HBP using an animal model of bone metastasis. In the rats treated with Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with Re-MAG3-HBP or Re-HEDP, but Re-MAG3-HBP tended to be more effective. These results indicate that Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain.
Re-MAG3-A7 anti-colorectal cancer monoclonal antibody; Comparison with 
I-counterpartKinuya, Seigo*; Yokoyama, Kunihiko*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Watanabe, Naoto*; Shuke, Noriyuki*; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*
Annals of Nuclear Medicine, 15(3), p.199 - 202, 2001/06
Times Cited Count：10 Percentile：33.17(Radiology, Nuclear Medicine & Medical Imaging)no abstracts in English
Re-labeled monoclonal antibodyKinuya, Seigo*; Yokoyama, Kunihiko*; Kudo, Miho*; Kasahara, Yoshihito*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*
Journal of Nuclear Medicine, 42(4), p.596 - 600, 2001/04
no abstracts in English
Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*
no journal, ,
no abstracts in English
Re-labeled antibody (A7) by a simple method using rhenium(I) tricarbonyl complexOgawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Yoshimoto, Mitsuyoshi*; Shiba, Kazuhiro*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
no journal, ,
Re is one of the most useful radionuclides for internal radiotherapy. However, there is a problem when protein such as antibody is used as a carrier of Re. The labeling method using bifunctional chelating agents require the conjugation of Re-complex to protein after radiolabeling with the bifunctional chelating agent. Then, we planned the preparation of a stable Re-labeled protein by a simple method. A7 monoclonal antibody was labeled by reacting Re(I) tricarbonyl precursor with A7 directly. Re labeled A7 was prepared with radiochemical yield of 23%. After purification, Re labeled A7 showed radiochemical purity over 98%. After 24 hours of incubation, about 93% of Re-A7 remained intact, which indicates Re-A7 is stable in vitro. In biodistribution experiment, 11.2% of the injected dose/g of Re-A7 accumulated in the tumor at 24 hours postinjection, and tumor to blood ratio was over 1.0 at the same time.
